Overview
CME Brief: Clinical Insights on Monkeypox
Expert Interview
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
The multi-country outbreak of monkeypox is now a global health emergency. Infections are being identified in areas where the virus is not usually found, and the transmission and presentation are following atypical patterns. In this activity, Dr. Joseph Osmundson discusses the current outbreak encompassing recognition, diagnosis, prophylactic strategies, and available treatments. Up-to-date resources are also included for reference.
(On November 28, 2022, the WHO recommended adoption of the synonym mpox for monkeypox disease)
This educational activity is designed for primary care physicians, pediatricians, public health professionals and other clinicians who may encounter patients with or at risk of contracting monkeypox.
An increasing number of monkeypox cases have been reported in the U.S and other countries that don’t normally report monkeypox. Clinicians require increased awareness of the growing risk of infection in high-risk populations to incorporate appropriate prophylactic strategies to prevent transmission. While there is no specific treatment approved for monkeypox virus infection, there are antiviral medications for the treatment of smallpox that may help patients with monkeypox. As such, clinicians require an understanding of these therapies and how to access them if needed.
Upon completion of this activity, participants will be able to:
-Outline the severity of monkeypox and implications for U.S. public health
-Incorporate CDC recommendations for pre-exposure prophylaxis to prevent monkeypox
-Formulate treatment strategies for optimizing care of diverse patients with or at risk for monkeypox
-Outline the severity of monkeypox and implications for U.S. public health
-Incorporate CDC recommendations for pre-exposure prophylaxis to prevent monkeypox
-Formulate treatment strategies for optimizing care of diverse patients with or at risk for monkeypox
This education is brought to you by the Academy for Continued Healthcare Learning (ACHL)
Joseph Osmundson, MS, PhD
Clinical Assistant Professor
Department of Biology
New York University
New York, NY
Clinical Assistant Professor
Department of Biology
New York University
New York, NY
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Joseph Osmundson, MS, PhD
No relationships to disclose
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: expanded-access use of ACAM2000, tecovirimat, vaccinia immune globulin, cidofovir, brincidofovir
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of commercial influence. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of any publisher or ineligible company.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to view the online activity and complete the evaluation. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
